Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort —

— Company to webcast... | September 16, 2022

Related Keywords

United States ,Washington ,Philadelphia ,Pennsylvania ,America ,American ,Joseph Rossano ,Heart Failure Society Of America ,Gaylord National Harbor Convention Center ,Nasdaq ,Meeting Of The American Society Gene ,Rocket Pharmaceuticals Inc ,Rocket Pharmaceuticals ,Disease Trial ,Heart Failure Society ,Annual Scientific Meeting ,Annual Meeting ,American Society ,Cell Therapy ,Safety Profile ,First Pediatric Cardiomyopathy Gene Therapy Trial ,Danon Disease ,Inherited Cardiomyopathies ,Cardiac Center ,Fanconi Anemia ,Leukocyte Adhesion Deficiency I ,Pyruvate Kinase Deficiency ,Nc Stock Exchange ,News ,Information ,Press Release ,Pdated ,Data ,Rom ,Hase , ,Qanon ,Disease ,Trial ,Xpected ,O ,Nclude ,Efficacy ,End ,Safety ,Pediatric ,Cohort ,Adult ,Company ,O Rckt Us77313f1066 ,